NLS Legal Advice

Elicera Therapeutics has received a Notice of Allowance from the Japan Patent Office (JPO) for its patent application covering the oncolytic virus candidate ELC-201 in solid tumors.

The company has entered a binding term sheet with BioMarin Pharmaceutical to settle all litigation over YUVIWEL (navepegritide), with BioMarin granting Ascendis a non-exclusive, worldwide, royalty-bearing license to continue developing and selling the drug without restriction.

Orexo has reached a non-binding agreement in principle on the main elements of a settlement with the US Department of Justice (DOJ) that would close an investigation ongoing since 2020.

Swedish cell and gene therapy company Elicera Therapeutics has received a Notice of Allowance from the US Patent and Trademark Office (USPTO) for a patent application protecting the antibodies behind its CAR T-cell candidate ELC-401 for glioblastoma.

Nykode Therapeutics has been granted a new US patent covering its individualized neoantigen cancer vaccine VB10.NEO and related modular vaccine designs, strengthening the company's intellectual property position as the neoantigen vaccine field gains momentum.

Klaria has received notification of patent approval from the European Patent Office regarding the second patent in the patent portfolio for Sumatriptan Alginate Film (SAF).